Business Overview: Microbot Medical Inc. (NASDAQ: MBOT)

---

Executive Summary

Microbot Medical Inc. is a medical device company developing robotic endovascular surgery systems. Its flagship product, the LIBERTY® Endovascular Robotic Surgical System, received FDA 510(k) clearance in September 2025 and entered limited market release in November 2025 — moving the company from a purely pre-revenue research-stage business into its earliest commercial-stage chapter.

The company has already shown rapid early commercial traction: revenue in the quarter ended June 30, 2026 was up more than 100% versus the prior quarter, with new hospital customers added in Massachusetts, North Carolina, Michigan, and Pennsylvania alongside existing customers in Georgia, Florida, and New York, and sales territories expanding from four to eight. This is still an early, small-revenue-base commercial launch, not a mature, profitable business.

---

1. Core Business Model & How They Work

[ LIBERTY Robotic System Sale/Placement ] ➡️ [ Hospital/Health System Adoption ] ➡️ [ Procedure Volume ] ➡️ [ Recurring Disposable/Service Revenue ]

Key Operational Drivers

1. Capital equipment plus consumables model: Like most surgical robotics companies, Microbot's commercial model is expected to combine system placements (capital sales or leases) with recurring, higher-margin disposable and service revenue tied to actual procedure volume.
2. Limited market release as a deliberate commercialization strategy: Rather than a full national rollout immediately after clearance, Microbot is expanding deliberately — new health systems and sales territories are being added methodically (four to eight sales territories as of mid-2026), which is typical for capital medical equipment requiring hospital capital-committee approval and physician training.
3. Endovascular robotics as a category: LIBERTY is designed to bring robotic precision and control to endovascular procedures (minimally invasive vascular interventions), a category where robotic assistance has historically lagged other surgical specialties (e.g., general/urologic robotic surgery).
4. Early customer wins across diverse geographies: New health system customers spanning Massachusetts, North Carolina, Michigan, and Pennsylvania, on top of existing customers in Georgia, Florida, and New York, suggest the product is resonating beyond a single early-adopter cluster.

---

2. Key Offerings

---

3. Competitive Landscape

Microbot's own disclosures do not name specific competitors. The broader endovascular and vascular robotics space has historically included players such as Corindus Vascular Robotics (acquired by Siemens Healthineers) and other medical robotics companies expanding into vascular applications, alongside traditional manual endovascular technique that remains the standard of care at most hospitals.

                 Robotic Precision/Control
                              ▲
                              │    Microbot Medical (LIBERTY)
   Siemens/Corindus            │          ●
   (established robotic entrant)│
   ───────────────────────────┼─────────────────────────►
                              │   Traditional Manual
                              │   Endovascular Technique
                              ▼
                 Established Standard of Care

Microbot's real competitive challenge is less about out-competing other robotics vendors directly and more about displacing the deeply entrenched manual technique that most vascular surgeons and interventional radiologists still use today.

---

4. Strategic Strengths & Risks

Strengths

• FDA clearance achieved: Having cleared the single biggest regulatory hurdle for a U.S. medical device, Microbot can now generate real commercial revenue rather than relying solely on capital raises.
• Rapid early revenue growth: More than 100% quarter-over-quarter revenue growth and expanding sales territories (four to eight) show genuine, if early, commercial momentum.
• Geographic diversification of early adopters: Customers spanning seven-plus states suggest broader market interest rather than a single regional pocket of demand.
• First-mover positioning in an underserved niche: Endovascular procedures have seen less robotic penetration than other surgical categories, giving Microbot room to establish itself before the category becomes crowded.

Risks

• Very early-stage commercialization: "Limited market release" status and still-small absolute revenue mean the company remains financially fragile and dependent on continued capital access while it scales.
• High cash burn relative to revenue: Prior reporting has highlighted a substantial gap between revenue and cash burn (on the order of low-hundreds-of-thousands in quarterly revenue against multi-million-dollar cash burn), a dynamic common to early-commercial medtech but a real risk if adoption doesn't accelerate.
• Hospital capital-equipment sales cycle: Selling into hospital systems involves lengthy capital-committee approval processes, which can slow the pace of system placements regardless of underlying physician interest.
• Competitive and substitution risk: Established robotics players with deeper resources (e.g., Siemens Healthineers' Corindus platform) could out-invest Microbot in physician training, clinical evidence generation, and sales infrastructure.

---

5. Financial Overview

---

Summary Conclusion

Microbot Medical has crossed the hardest threshold for a medical device company — FDA clearance — and is now in the early, fragile, but genuinely promising commercialization phase for its LIBERTY robotic endovascular system. Rapid sequential revenue growth and expanding sales territories are real positive signals, but the company is still operating at a small revenue base relative to its cash needs, in a capital-equipment category with inherently long hospital sales cycles. The investment case here is squarely about execution risk in scaling adoption fast enough to outrun cash burn, not about product viability, which the FDA clearance and early customer wins have already substantially validated.